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Abstract 
Chondrogenic differentiation of adipose derived stem cells (ASC) is challenging but 
highly promising for cartilage repair. Large donor variability of chondrogenic 
differentiation potential raises the risk for transplantation of cells with reduced efficacy 
and a low chondrogenic potential. Therefore quick potency assays are required in 
order to control the potency of the isolated cells before cell transplantation. Current in 
vitro methods to analyze the differentiation capacity are time consuming and thus, a 
novel enhancer and tissue-specific promoter combination was employed for the 
detection of chondrogenic differentiation of ASC in a novel quick potency bioassay. 
Human primary ASC were co-transfected with the Metridia luciferase based collagen 
type II reporter gene pCMVE_ACDCII-MetLuc together with a Renilla control plasmid 
and analyzed for their chondrogenic potential. On day 3 after chondrogenic induction, 
the luciferase activity was induced in all tested donors under three dimensional (3D) 
culture conditions and in a second approach also under 2D culture conditions. With 
our newly developed quick potency bioassay we can determine chondrogenic 
potential already after 3 days of chondrogenic induction and under 2D culture 
conditions. This will enhance the efficiency of testing cell functionality, which should 
allow in the future to predict the suitability of cells derived from individual patients for 
cell therapies, in a very short time and at low costs. 
  
		
Introduction 
Cartilage repair strategies after traumatic injuries range from standard autologous 
cartilage transplantation (mosaicplasty) or marrow-stimulating techniques 
(microfracture) up to novel cell based strategies. For the matrix associated 
chondrocyte transplantation (MACT) 1, biomaterials are used in combination with 
expanded human autologous chondrocytes (hAC), a method which originates from a 
scaffold free procedure, the autologous chondrocyte transplantation (ACT) 2. One of 
the biggest drawbacks of cartilage/chondrocyte based methods is that healthy 
autologous cartilage needs to be harvested from the patient. This creates an 
additional defect which enhances the risk for developing osteoarthritis. In order to 
obtain enough cells for treatment it is further necessary to expand chondrocytes in 
vitro which is accompanied by a dedifferentiation process, leading to fibroblast-like, 
collagen type I expressing cells 3. Instead of hAC, mesenchymal stem cells (MSC) 
may overcome drawbacks accompanied with cartilage harvest and cell expansion. 
Bone marrow-derived MSC (BMSC) represent the most intensively investigated MSC 
type in cartilage tissue engineering. They can be isolated from bone marrow 
aspirates, expanded in monolayer and induced for chondrogenic differentiation 4, 5. 
Zuk et al. found that adipose-derived stem cells (ASC) also show ability to form 
cartilage-like matrix, as indicated by Alcian blue and collagen type II staining 6. In 
contrast to bone marrow, adipose tissue can be harvested in large amounts by 
simple surgical procedure. However, a large donor variability for the chondrogenic 
differentiation potential has been reported 7, 8, which raises the risk for transplantation 
of low-potent cells. Therefore, a quick potency assay is required to predict cell 
potency before transplantation or long-term storage. For assessing the chondrogenic 
potential collagen type II might be regarded as the most specific and unique marker 
for hyaline cartilage synthesis. Unfortunately, collagen type II expression starts very 
		
late: a significant increase can be detected by quantitative reverse transcription- 
(qRT) PCR after 2-3 weeks of differentiation in vitro 7 which impedes quick decisions 
of cells’ quality. This late but specific marker needs to be monitored in an early phase 
to anticipate cellular alteration and modification upon differentiation. Therefore we 
designed and developed a luciferase-based reporter-vector together with a quick 
potency assay to monitor the capability of cells synthesizing collagen type II upon 
chondrogenic induction. Luciferase based bioassays represent a useful alternative to 
conventional analytical methods due to their simple and extremely sensitive 
properties. The assay employed in this work is based on measuring bioluminescence 
derived from the reaction of Metridia luciferase under control of a tissue-specific 
collagen type II promoter coupled to a signal amplified viral enhancer (CMV) 9. With 
our luciferase reporter system we have established a proof of principle concept for 
the prediction of the chondrogenic differentiation potential within 3 days.  
 
Methods 
ASC isolation and cultivation 
The collection of human tissue was approved by the local ethical board with patient’s 
consent. Subcutaneous human adipose tissue was obtained during routine outpatient 
liposuction procedures under local tumescence anaesthesia. Isolation of ASC was 
performed according to Wolbank et al. 10. After isolation, cells were cultured in 
endothelial growth medium (EGM-2; Lonza, Austria) at 37°C, 5% CO2, and 95% air 
humidity to a subconfluent state before passaging. ASC were seeded at a density of 
2x103 / cm2 and media was changed every 3-4 days. ASC from passage 1 were used 
		
for flow cytometry, histological analysis and reporter experiments. For qRT-PCR 
experiments cells were expanded up to passage 2-4. 
   
ASC immunophenotype  
ASC from passage 1 were characterized by flow cytometry analysis using the 
following antibodies: CD73-PE (BD), CD90-PE (BD), CD105-FITC (Abcam), CD14-
FITC (Immunotools), CD34-PE (Immunotools), CD45-FITC (BD), HLA-ABC-PE (BD) 
and HLA-DR-FITC (BD). For staining, 2x105 cells in 50 µL PBS with 1% FCS were 
incubated with 5 µl primary labeled antibodies at room temperature for 15 min in the 
dark. Cells were washed with 1.5 ml Cell Wash™ (BD) and centrifuged for 5 min at 
400 g. The supernatant was discarded and the cell pellet resuspended in 300 µL 1 x 
Cell Fix™ (BD; diluted 1:10 with aqua dest) and analyzed on a FACSCanto (BD).  
 
Chondrogenic 3D pellet culture 
For chondrogenic differentiation and 3D micromass pellet cultures 3x105 ASC were 
centrifuged in chondrogenic differentiation media (hMSC Chondro BulletKit (Lonza) 
containing 10ng/ml BMP-6 (R&D Systems, Austria) and 10ng/ml TGF-ß3 (Lonza)) in 
1.5 mL polypropylene screw cap micro tubes (Sarstedt, Austria). The tubes were 
placed in an incubator at 37°C, 5% CO2, and 95% humidity with slightly open cap for 
gas exchange. After 2 days the pellets were transferred to 96-well U-bottom plates. 
Media was changed every 2-3 days. 
 
Histological analysis 
		
The 3D micromass pellet cultures incubated over 35 days in chondrogenic 
differentiation media were measured once a week for their cross section area. 
Micromass pellets were fixed in 4% phosphate-buffered formalin overnight for 
histological analysis. The next day the pellets were washed in 1x PBS and 
dehydrated in increasing concentrations of alcohol. After rinsing the pellets in xylol 
and infiltration with paraffin, deparaffinized sections were stained with Alcian blue for 
30 min and counterstained for 2 min with Mayers haematoxylin. For 
immunohistochemical staining, sections were treated with pepsin for 10 min at 37°C 
(AP-9007 RTU, Thermo Scientific, Austria). Endogenous peroxidase was quenched 
with freshly prepared 3% H2O2 for 10 min at room temperature, followed by normal 
horse serum 2.5% (Vector RTU) to block unspeciﬁc binding. Sections were incubated 
1 hour with monoclonal anti- collagen type II (MS-306 P0 Thermo Scientific) at 1:100. 
After washing with TBS, sections were incubated with the secondary antibody (anti 
mouse DAKO EnVision+ System HRP labelled Polymer, Dako, Austria) for 30 min 
and rinsed in TBS again. Bindings were visualized using Nova Red (SK4800 Vector 
Labs, Austria) for 6 min. Counterstaining was performed with Mayers haematoxylin 
for 2 min. For quantification of the collagen type II immunohistolgical staining intensity 
ImageJ 1.47v (National Institutes of Health, USA) was used. 
 
Quantitative RT-PCR 
Samples for qRT–PCR were taken after 3 days and at the end of differentiation 
cultures (day 35). Three to five micromass pellets per donor were pooled in 1 ml 
TriReagent (Sigma) and incubated for 20 min at room temperature. Extraction was 
facilitated by repeated pipetting of the pellets. Total RNA isolation was performed 
according to the TriReagent protocol (Sigma) and RNA content and RNA integrity of 
		
the samples was assessed by an Agilent 2100 Bioanalyzer, using the RNA 6000 
Nano Chips Kit (no. 5065 – 4476, Agilent Technologies, Germany). Isolated RNA 
was transcribed to cDNA according to the High Capacity cDNA Archive Kit protocol 
(Applied Biosystems, Austria). Quantiﬁcation of speciﬁc cDNAs was conducted in 
triplicate, using a LightCycler W 480 (Roche, Germany) and Taqman gene 
expression assay (Applied Biosystems) for Col2A1 (collagen type II, 
Hs01064869_m1) and Sox9 (Hs00165814_m1). The PCR was programmed as 
follows: initial denaturation at 95°C for 10 min, followed by 95°C for 10 s, 60°C for 45 
s, cycled 50 times. Cooling to 40°C was held for 30 s. Slope speed was 20°C/s. 
Standard curves were prepared for quantiﬁcation and expression values were 
normalized to the housekeeping gene, hypoxanthine–guanine phosphoribosyl 
transferase (HPRT). The efﬁciency-corrected quantiﬁcation was performed 
automatically, using LightCycler 480 Relative Quantiﬁcation Software (Roche). 
 
Reporter plasmid 
All cloning procedures were carried out using a standard Taq hot-start polymerase 
(Peqlab Biotechnologie GesmbH, Austria) and the E.coli cloning strain TOP10. The 
human collagen II alpha 1 promoter (Col2A1 promoter and 5’ mRNA UTR from -478 
to +179 from the transcriptional start site, see NC_000012.12) was cloned from 
human genomic DNA isolated from whole blood using the cloning primers hColIIPs 
5’- CTGTGGGCTCCTCCCTGTCCCCACTCC-3’) and hColIIPas(NotI) (5’- 
GAGGCGGCCGCGCTCACCGCGGGGCCTGGCTGAGC-3’) (Microsynth AG, 
Switzerland) and the product was ligated into the vector pCR2.1 by TA cloning for 
sequencing (data not shown) and subsequent cloning. The promoter was transferred 
to the in-house designed plasmid pCMVE-EYFPHis containing the CMV-enhancer 
		
(from -524 to -120 from the transcriptional start site, according to 9) and an EYFPHis 
reporter gene by PCR amplification using the primers hC2PHIII_f. (5’-GAG AAG CTT 
CTG TGG GCT CCT CCC TGT CC-3’) and hC2PHIII_r (5’-GAG AAG CTT GCT CAC 
CGC GGG GCC TGG-3’) (Microsynth AG), transfer of the PCR product to pCR2.1 
and subsequent cloning by HindIII (Fermentas/FisherScientific, Austria) digestion of 
insert and destination vector and ligation into pCMVE_ACDCII using standard 
procedures. The EYFPHis reporter gene was exchanged by a Metridia secreted 
luciferase by cloning the Metridia luciferase open reading frame 3’ of the CMV 
enhancer and the collagen II promoter in pCMVE_ACDCII using AgeI 
(Fermentas/FisherScientific) and NotI (Fermentas/FisherScientific) restriction sites. 
All vectors and intermediate products were verified by control digests (data not 
shown) and the Metridia luciferase containing end product pCMVE_ACDCII-MetLuc 
(Col2A, Fig. 1) was verified by sequencing (data not shown).  
 
Luciferase assay 
Pellets were co-transfected with Metridia luciferase based reporter genes 
pCMVE_ACDCII-MetLuc together with the Renilla control plasmid using X-
tremeGENE HP DNA Transfection Reagent (Roche) and 0.4 µg DNA in a 3:1 
reagent/DNA ratio after 2 days of pellet formation. For chondrogenic 2D luciferase 
assay 3x104 ASC per well were seeded in a white 96 well plate (Fisher Scientific, 
Austria) in EGM-2 media (9.4x104 / cm2). Sixteen hours later media was replaced by 
differentiation media. ASC were co-transfected with Metridia luciferase based 
reportervector pCMVE_ACDCII-MetLuc together with Renilla control plasmid using 
the same concentrations like for 3D pellet transfection. Metridia luciferase activity 
was measured in the supernatant samples (50 µl) with Ready-To-Glow™ Secreted 
		
Luciferase Reporter System (Clontech, Austria) according to the manufacturer’s 
protocol on day 1, day 2 and day 3. For the evaluation of this bioassay and as 
internal control to normalize the transfection we co-transfected the cells with a Renilla 
reporter gene under control of an ubiquitary promoter. Prior to measurement of 
Renilla luciferase activity, ASC were lysed with 1x Renilla Luciferase Assay Lysis 
Buffer (Promega, Austria) for 15 minutes, pellets with 5x Renilla Luciferase Assay 
Lysis Buffer for 15 minutes at 1400 rpm. Then Renilla luciferase activity was 
measured using Renilla Luciferase Assay System (Promega) according to the 
manufacturer’s instructions. Luciferase activities were recorded with an Infinite→ 
M200 Multimode Microplate Reader (Tecan). Data were normalized for transfection 
efficiency to Renilla luciferase activity. Pellet cultures and adherent cells were 
transfected using green fluorescent protein (GFP) to evaluate transfection efficiency. 
GFP positive pellets and cells were microscopically analyzed (Axiovert 200, Zeiss, 
Germany). 
 
Statistical Analysis  
Data are presented as mean ± standard deviation and statistical analysis was 
performed using PRISM6 (GraphPad, San Diego, CA, USA). P values of < 0.05 were 
considered to be significant acquired by parametric 2-way analysis of variance 
(ANOVA)-Bonferroni post hoc or parametric two-tailed t-test assuming normal 
distribution according to Kolmogorov-Smirnov normality test. 
 
Results 
Expression of specific ASC surface marker  
		
ASC displayed strong expression of mesenchymal stem cell marker CD73 (99.68% ± 
0.35), CD90 (98.70% ± 1.46) and CD105 (97.95% ± 1.62) and almost no expression 
of the lymphatic marker CD14 (1.64% ± 0.87), the endothelial marker CD34 (3.90% ± 
7.69) and the hematopoietic marker CD45 (1.23% ± 0.52) (Suppl. Table 1), which 
verified the ASC character as described in Bourin et al. 2013 11. The 
histocompatibility antigen molecule HLA-ABC (93.74% ± 6.17) was expressed at a 
very high level whereas only a small portion of ASC expressed the histocompatibility 
antigen class II HLA-DR (1.71% ± 0.76). 
 
Definition of donor potential by qRT-PCR, histology and pellet diameter area  
 
Micromass pellets from 9 different donors were analyzed after 35 days of 
chondrogenic differentiation for their capability to express collagen type II at mRNA 
and protein level by means of qRT-PCR and immunohistological staining. Further, 
sulphated glycosaminoglycans (sGAGs) were stained with Alcian blue to analyze the 
potential of individual donors to synthesize proteoglycans. Donors 3, 4, 5, 8 and 9 
showed Col2A1 expression levels in the range of 70.8-354.8 (relative mRNA 
expression normalized to HPRT), whereas donors 1, 2, 6 and 7 demonstrated 
significantly lower values in the range of 0.0066 – 3.4 (Fig. 2a,b). Immunohistological 
stainings showed that donors with low Col2A1 mRNA expression have also low 
potential to produce collagen type II and sGAGs on protein level, while donors with 
high Col2A1 expression on mRNA level showed intense staining for Alcian blue and 
collagen type II (Fig. 3a). Based on the results of qRT-PCR and histological 
evaluations we defined donors with high and low differentiation potential, as “good 
donors” and “bad donors”. The pellet diameter area of each good and bad donor was 
evaluated over time in culture (day 7, 14, 21, 28 and 35) (Fig. 3b). These results 
		
corroborate the immunohistological stainings for Alcian blue and collagen type II. 
Donor 2  is in the range of the good donors regarding pellet diameter area but is still 
negative for Alcian blue and collagen type II staining.. According to the analyses, the 
threshold for Col2A1 expression on mRNA level was set to 10 and together with the 
histological and immunohistological data we identified 5 good donors (3, 4, 5, 8, 9) 
and 4 bad donors (1, 2, 6, 7). 
 
Activation of Col2A luciferase reporter under 3D culture conditions 
To visualize transfection efficiency of 3D micromass pellets a GFP plasmid was used 
(Suppl. Fig. 1a). The weak fluorescence of un-transfected pellets is probably due to 
the known autofluorescence of cartilage-like matrix 12. For the analysis of Col2A 
reporter activation micromass pellets of the 9 different donors were transfected with a 
plasmid containing Metridia luciferase under control of the Col2A promoter together 
with a plasmid containing Renilla luciferase under control of an ubiquitary promoter. 
After 3 days of differentiation the activation of the Col2A luciferase reporter was 
analyzed and normalized to Renilla luciferase. While there were remarkable 
differences in the activation of the Col2A reporter (Fig. 4a), all donors showed similar 
activation of Renilla luciferase (Fig. 4b), indicating similar transfection efficiency and 
promoter activation. These differences in the Col2A reporter activation also occurred 
after normalization to Renilla activation (Fig. 4c). The data were compared to the 
results of qRT-PCR and histological stainings. Good donors exhibited relative 
luciferase units (RLU) in the range of 5.0x104-8.9x104 of Col2A activation 
corresponding to relative values of 112-335 after normalization to Renilla, while bad 
donors were in the range of 5.5x103-3.4x104 and 20.1-95.7 after normalization (Fig. 
4a,c). Sequential analysis of Col2A reporter activation over the first 3 days of 
induction showed an increase for both groups, but significantly higher Col2A 
		
activation for good donors on day3 (Fig. 4d). Even after normalization of Col2A 
activation to Renilla activation the induction of Col2A reporter was significantly 
stronger in good donors (199 ± 83) compared to bad donors (51 ± 34) (Fig. 4e). 
 
Col2A1 and Sox9 mRNA expression under 3D culture conditions 
As we have observed a luciferase reporter signal only after 3 days of differentiation 
we performed qRT-PCR for Col2A1 and Sox9. After 3 days Col2A1 expression was 
not detectable for any donor except minimal levels for donor 2 (Col2A1 mRNA 
expression of 0.0154) (data not shown). Early marker Sox9 expression after 3 days 
of differentiation showed also a very low but detectable signal in all donors (Suppl. 
Fig. 2a). However no difference between bad and good donors could be 
discriminated (Suppl. Fig. 2b). 
 
Activation of Col2A luciferase reporter under 2D culture conditions 
 
In order to simplify the assay we changed from the standard chondrogenic 3D culture 
conditions to 2D culture conditions, which reduces time and required cell numbers. 
Transfection efficiency was analyzed by using a GFP plasmid (Suppl. Fig. 1b) 
corresponding to 45.3% ± 11.8 of transfected cells as determined by nucleocounting. 
ASC were seeded and induced in 2D culture and co-transfected with Col2A reporter 
plasmid together with Renilla luciferase control plasmid. There was a clear difference 
in the activation of Col2A reporter between good (6.2x105-1.1x106 RLU) and bad 
donors (2.4x105-7.0x105 RLU) found on day 3 of culture (Fig. 5a), while Renilla 
activation was similar in all tested donors (Fig. 5b). The differences in Col2A reporter 
activation were still present after normalization of Metridia to Renilla activation (19.9-
		
31.3 vs. 7.3-18.3) (Fig. 5c), which demonstrates that the potential for chondrogenic 
differentiation is reflected in Col2A promoter activity at early timepoints even under 
2D conditions. Sequential analysis of Col2A reporter activation over the first 3 days 
showed an increase for both groups, but again a significantly higher Col2A activation 
for good versus bad donors on day 3 (Fig. 5d). Moreover, activation of Col2A reporter 
was still higher in good donors (25.6 ± 4.3) compared to bad donors (14.2 ± 4.8) after 
normalization to Renilla activation (Fig. 5e). 
 
Relation of Col2A luciferase reporter activation to Col2A1 mRNA expression, 
collagen type II immunostaining or pellet diameter area  
For a more clear relation of the 3D micromass pellet data, our day 3 quick potency 
assay was plotted against qRT-PCR, immunostainings and pellet diameter area of 
day 35 3D cultures (Fig. 6).  
By comparing values of Col2A luciferase reporter activation to Col2A1 mRNA 
expression (Fig. 6a) as well as to colIagen type II immunostaining intensity (Fig. 6b)  
the determined good donors 3, 4, 5, 8, 9 and bad donors 1, 2, 6, 7 could clearly be 
identified. Regarding the relation between Col2A luciferase reporter activation and 
the pellet diameter area (Fig. 6c) there is no clear cut-off line to identify donor quality, 
which may however partly be due to the low correlation of pellet size and the quality 
of chondrogenic differentiation 13, 14.  
	
Discussion 
 
		
In the current study we developed a quick potency assay for fast determination of 
chondrogenic differentiation status of ASC. ASC can be induced for collagen type II 
expression after extensive passaging 15, but also directly after isolation from adipose 
tissue 16. The expression of collagen type II is mainly regulated via the TGF-ß 
pathway 17, 18; in a previous work we could demonstrate that TGF-β and BMP-6 
induce collagen type II expression in ASC, in a 3D culture system 19.	 Also other 
pathways such as MAPK- and Wnt/β-catenin signalling have impact on collagen type 
II expression but have not been investigated in detail as the TGF-β pathway 21-25. To 
predict chondrogenic potential of ASC from different donors, Kang et al. measured 
activation of TGF-ß receptor expression. The chondrogenic potential was increased 
with a bicistronic vector system containing TGF-ß receptors 20. Duryagina et al. 
developed a new reporter system based on Gaussia luciferase reporter to monitor 
HSC-supportive proteins in human MSC 21. The advantages of assessing reporter 
genes with bioluminescent assays are the high sensitivity and the non-destructive 
and rapid application compared to protein and RNA analysis 22.  Based on a previous 
study, where we designed a reporter construct for detection of osteogenic 
differentiation 9, we employed in this study a novel reporter for chondrogenic 
differentiation. Cells from 4 individuals demonstrated a value for Col2A1 relative 
mRNA expression lower than 5 which confirmed the weak Alcian blue and absent 
immunohistological staining for collagen type II. These donors were regarded as bad 
donors. The remaining 5 donors expressed Col2A1 in the range of 70-350 and 
showed intense Alcian blue and collagen type II expression on protein level. These 
donors were regarded as good donors. The pellet diameter area of each good and 
bad donor corroborate these results, except donor 2 which is in the range of the good 
donors but still negative for Alcian blue and collagen type II staining. This is slightly 
different to a study of Hennig et al. 7, who investigated the chondrogenic 
		
differentiation potential of 9 donors treated with TGF-β and BMP-6 resulting in 7 of 9 
donors positive for collagen type II immunohistochemistry and all investigated 
samples positive for Col2A1 gene expression. They also found that low potency 
donors lack the expression of TGF-β receptor I which could be partly overcome by 
co-induction with TGF-β and BMP-6 7. We have identified that 20-50% are low 
potency donors (with low or no collagen type II expression) also in presence of BMP-
6, there is need for further analysis to find out differences between good and bad 
donors.  
Our determined good and bad donors were evaluated with our reporter gene assay 
using the identical differentiation condition and compared to collagen type II 
expression on mRNA and protein level on day 35. To our knowledge we were the first 
who showed transfection of chondrogenic micromass pellet cultures. The results of 
the quick potency assay measured for Metridia luciferase in the supernatant showed 
an increase of Col2A promoter activation for all donors from 1- 3 days with significant 
higher values of the good donors on day 3. Even the values normalized for Renilla 
luciferase activity were significantly higher for the good donors. Notably, the Col2A 
reporter activation normalized against Renilla demonstrated higher values in each of 
the good donors compared to each single bad donor. These results corroborate the 
analyses of the histological stainings and qRT-PCR after 35 days with 5 good donors 
and 4 bad donors. At single donor level, Col2A luciferase reporter activation 
measured on day 3 was comparable to the readout from day 35 pellet culture Col2A1 
mRNA levels and immunostaining for collagen type II and Alcian blue. We could 
hence identify the 4 donors with the weakest potential for chondrogenesis resulting in 
no deposition of collagen 2 in the pellets after 5 weeks. This result based on Col2A 
promoter-activity could be achieved although Col2A is a late marker and Col2A1 
mRNA levels on day 3 were indeed negative. mRNA levels of the early marker Sox9 
		
could be detected in all 9 donors already on day 3. However expression levels were 
extremely low and did not allow identification of the previously determined donors 
obtained by Col2A1 mRNA level and immunostainings on day 35. Hence, Sox9 
expression on day 3 was not predictive for chondrogenic potency at an early time 
point. Although 3D micromass pellet culture is the prerequisite for induction of 
chondrogenic differentiation we simplified this assay and changed to 2D culture. 
Surprisingly, also under 2D culture conditions Col2A reporter activity increased over 
3 days for all donors with a significant difference on day 3. The change from 3D to 2D 
contributed towards further improvement by saving time (2 days less, since no pellet 
formation was necessary) and cell number (1/10) while maintaining the functionality 
of the assay. Moreover, under 2D conditions no autofluorescence was visible which 
interferes with the luciferase reporter signal. Considering absolute Metridia (Fig. 4a, 
Fig. 5a) and Renilla (Fig. 4b, Fig. 5b) values, obviously 2D culture conditions give 
higher signals compared to 3D culture conditions. This might be due to inferior 
transfection or cell lysis efficiency in 3D micromass pellets compared to monolayer 
cultures. However, Metridia values normalized against Renilla are higher under 3D 
(Fig. 4c,e) than under 2D (Fig. 5c,e) culture conditions, which confirms the fact that 
ASC cultured in micromass pellets are more committed to the chondrogenic lineage 
compared to 2D culture. The results demonstrate that a determination between good 
and bad donors is possible under both 3D and 2D conditions. That implies the 
functionality and quality of the assay is maintained combined with the advantages of 
a quick potency assay.  
In this study we have established a proof of principle concept for the analysis of 
donor quality in terms of chondrogenic differentiation potential.	Based on this study 
the identification of donor material with poor chondrogenic differentiation potential 
should allow to exclude these cells at early timepoints. Before an implementation as 
		
a valuable cGMP (current good manufacturing practice) quality control could be 
established in the future, further careful evaluation of the cut-off point with a high 
number of donors would be required. 
 
Acknowledgements 
We thank Ludwig Aigner from Paracelsus Medical University (PMU) in Salzburg, 
Austria for providing Renilla control plasmid. This work was funded by grant from the 
Austrian Research Promotion Agency (FFG) (Bridge1 programme, grant No.846062). 
 
Author Disclosure Statement 
The authors declare that they have no competing interests. The authors alone are 
responsible for the content and writing of this paper. 
 
Address correspondence to: 
Eleni Oberbauer, PhD 
Ludwig Boltzmann Institute for Experimental and Clinical Traumatology 
Krankenhausstraße 7 
4010 Linz 
Austria 
E-Mail: Eleni.Oberbauer@o.roteskreuz.at 
 
 
 
 
		
Reference List 
1.	 	Marlovits,	 S.,	 Zeller,	 P.,	 Singer,	 P.,	 Resinger,	 C.,	 and	 Vecsei,	 V.	 Cartilage	 repair:	 generations	 of	
autologous	chondrocyte	transplantation.	European	journal	of	radiology	57,	24,	2006.	
2.		Brittberg,	M.,	Lindahl,	A.,	Nilsson,	A.,	Ohlsson,	C.,	Isaksson,	O.,	and	Peterson,	L.	Treatment	of	deep	
cartilage	defects	in	the	knee	with	autologous	chondrocyte	transplantation.	The	New	England	journal	
of	medicine	331,	889	1994.	
3.	 	 Schlegel,	 W.,	 Albrecht,	 C.,	 Eckl,	 P.,	 Freudenthaler,	 H.,	 Berger,	 A.,	 Vecsei,	 V.,	 and	 Marlovits,	 S.	
Dedifferentiation	 of	 human	 articular	 chondrocytes	 is	 associated	 with	 alterations	 in	 expression	
patterns	of	GDF-5	and	its	receptors.	Journal	of	cellular	and	molecular	medicine	13,	3398,	2009.	
4.	 	 Johnstone,	 B.,	 Hering,	 T.,	 Caplan,	 A.,	 Goldberg,	 V.,	 and	 Yoo,	 J.	 In	 vitro	 chondrogenesis	 of	 bone	
marrow-derived	mesenchymal	progenitor	cells.	Experimental	cell	research	238,	265	1998.	
5.	 	 Mackay,	 A.,	 Beck,	 S.,	 Murphy,	 J.,	 Barry,	 F.,	 Chichester,	 C.,	 and	 Pittenger,	 M.	 Chondrogenic	
differentiation	of	cultured	human	mesenchymal	stem	cells	 from	marrow.	Tissue	engineering	4,	415	
1998.	
6.	 	 Zuk,	P.A.,	 Zhu,	M.,	Mizuno,	H.,	Huang,	 J.,	 Futrell,	 J.W.,	Katz,	A.J.,	Benhaim,	P.,	 Lorenz,	H.P.,	 and	
Hedrick,	M.H.	Multilineage	 cells	 from	 human	 adipose	 tissue:	 implications	 for	 cell-based	 therapies.	
Tissue	engineering	7,	211,	2001.	
7.	 	 Hennig,	 T.,	 Lorenz,	 H.,	 Thiel,	 A.,	 Goetzke,	 K.,	 Dickhut,	 A.,	 Geiger,	 F.,	 and	 Richter,	W.	 Reduced	
chondrogenic	 potential	 of	 adipose	 tissue	 derived	 stromal	 cells	 correlates	with	 an	 altered	 TGFbeta	
receptor	and	BMP	profile	and	is	overcome	by	BMP-6.	Journal	of	cellular	physiology	211,	682,	2007.	
8.		Hildner,	F.,	Eder,	M.J.,	Hofer,	K.,	Aberl,	J.,	Redl,	H.,	van	Griensven,	M.,	Gabriel,	C.,	and	Peterbauer-
Scherb,	A.	Human	platelet	 lysate	successfully	promotes	proliferation	and	subsequent	chondrogenic	
differentiation	 of	 adipose-derived	 stem	 cells:	 a	 comparison	with	 articular	 chondrocytes.	 Journal	 of	
tissue	engineering	and	regenerative	medicine	2013.	
9.	 	 Feichtinger,	 G.A.,	 Morton,	 T.J.,	 Zimmermann,	 A.,	 Dopler,	 D.,	 Banerjee,	 A.,	 Redl,	 H.,	 and	 van	
Griensven,	M.	Enhanced	reporter	gene	assay	 for	 the	detection	of	osteogenic	differentiation.	Tissue	
engineering	Part	C,	Methods	17,	401,	2011.	
10.		Wolbank,	S.,	Peterbauer,	A.,	Fahrner,	M.,	Hennerbichler,	S.,	van	Griensven,	M.,	Stadler,	G.,	Redl,	
H.,	 and	Gabriel,	 C.	 Dose-dependent	 immunomodulatory	 effect	 of	 human	 stem	 cells	 from	 amniotic	
membrane:	 a	 comparison	 with	 human	 mesenchymal	 stem	 cells	 from	 adipose	 tissue.	 Tissue	
engineering	13,	1173,	2007.	
11.	 	Bourin,	P.,	Bunnell,	B.A.,	Casteilla,	L.,	Dominici,	M.,	Katz,	A.J.,	March,	K.L.,	Redl,	H.,	Rubin,	 J.P.,	
Yoshimura,	 K.,	 and	 Gimble,	 J.M.	 Stromal	 cells	 from	 the	 adipose	 tissue-derived	 stromal	 vascular	
fraction	 and	 culture	 expanded	 adipose	 tissue-derived	 stromal/stem	 cells:	 a	 joint	 statement	 of	 the	
International	Federation	for	Adipose	Therapeutics	and	Science	(IFATS)	and	the	International	Society	
for	Cellular	Therapy	(ISCT).	Cytotherapy	15,	641,	2013.	
12.	 	 Hagiwara,	 Y.,	 Hattori,	 K.,	 Aoki,	 T.,	 Ohgushi,	 H.,	 and	 Ito,	 H.	 Autofluorescence	 assessment	 of	
extracellular	matrices	of	a	cartilage-like	tissue	construct	using	a	fluorescent	 image	analyser.	Journal	
of	tissue	engineering	and	regenerative	medicine	5,	163,	2011.	
13.		Payne,	K.A.,	Didiano,	D.M.,	and	Chu,	C.R.	Donor	sex	and	age	influence	the	chondrogenic	potential	
of	 human	 femoral	 bone	 marrow	 stem	 cells.	 Osteoarthritis	 and	 cartilage	 /	 OARS,	 Osteoarthritis	
Research	Society	18,	705,	2010.	
14.	 	 Shirasawa,	 S.,	 Sekiya,	 I.,	 Sakaguchi,	 Y.,	 Yagishita,	 K.,	 Ichinose,	 S.,	 and	 Muneta,	 T.	 In	 vitro	
chondrogenesis	 of	 human	 synovium-derived	 mesenchymal	 stem	 cells:	 optimal	 condition	 and	
comparison	with	bone	marrow-derived	cells.	Journal	of	cellular	biochemistry	97,	84,	2006.	
15.	 	 Estes,	 B.T.,	 Wu,	 A.W.,	 Storms,	 R.W.,	 and	 Guilak,	 F.	 Extended	 passaging,	 but	 not	 aldehyde	
dehydrogenase	activity,	 increases	the	chondrogenic	potential	of	human	adipose-derived	adult	stem	
cells.	Journal	of	cellular	physiology	209,	987,	2006.	
16.	 	 Jurgens,	W.J.,	van	Dijk,	A.,	Doulabi,	B.Z.,	Niessen,	F.B.,	Ritt,	M.J.,	van	Milligen,	F.J.,	and	Helder,	
M.N.	Freshly	isolated	stromal	cells	from	the	infrapatellar	fat	pad	are	suitable	for	a	one-step	surgical	
procedure	to	regenerate	cartilage	tissue.	Cytotherapy	11,	1052,	2009.	
		
17.	 	 Moustakas,	 A.,	 Souchelnytskyi,	 S.,	 and	 Heldin,	 C.H.	 Smad	 regulation	 in	 TGF-beta	 signal	
transduction.	Journal	of	cell	science	114,	4359,	2001.	
18.	 	Heldin,	 C.,	Miyazono,	 K.,	 and	 ten	Dijke,	 P.	 TGF-beta	 signalling	 from	 cell	membrane	 to	nucleus	
through	SMAD	proteins.	Nature	390,	465	1997.	
19.		Hildner,	F.,	Peterbauer,	A.,	Wolbank,	S.,	Nurnberger,	S.,	Marlovits,	S.,	Redl,	H.,	van	Griensven,	M.,	
and	Gabriel,	C.	FGF-2	abolishes	the	chondrogenic	effect	of	combined	BMP-6	and	TGF-beta	in	human	
adipose	derived	stem	cells.	Journal	of	biomedical	materials	research	Part	A	94,	978,	2010.	
20.	 	 Kang,	 S.W.,	 Do,	 H.J.,	 Han,	 I.B.,	 Shin,	 D.A.,	 Kim,	 H.O.,	 Kim,	 J.H.,	 and	 Lee,	 S.H.	 Increase	 of	
chondrogenic	potentials	in	adipose-derived	stromal	cells	by	co-delivery	of	type	I	and	type	II	TGFbeta	
receptors	 encoding	 bicistronic	 vector	 system.	 Journal	 of	 controlled	 release	 :	 official	 journal	 of	 the	
Controlled	Release	Society	160,	577,	2012.	
21.	 	 Duryagina,	 R.,	 Anastassiadis,	 K.,	Maitz,	M.F.,	 Gramm,	 S.,	 Schneide,	 S.,	Wobus,	M.,	 Thieme,	 S.,	
Brenner,	 S.,	 Werner,	 C.,	 and	 Bornhauser,	 M.	 Cellular	 Reporter	 Systems	 for	 High-Throughput	
Screening	of	Interactions	Between	Bioactive	Matrices	and	Human	Mesenchymal	Stromal	Cells.	Tissue	
engineering	Part	C,	Methods	2014.	
22.	 	 Fan,	 F.,	 and	Wood,	 K.V.	 Bioluminescent	 assays	 for	 high-throughput	 screening.	Assay	 and	drug	
development	technologies	5,	127,	2007.	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
		
 
 
 
 
 
 
 
Fig. 1.  Metridia luciferase based reportervector pCMVE_ACDCII-MetLuc. This 
construct utilizes an artificial, chimeric cis-acting regulatory sequence through 
combination of a pan-active cytomegalovirus enhancer cloned directly upstream of 
the human COL2A promoter which drives the expression of the reporter gene.  
 
 
		
Fig. 2. COL2A1 mRNA expression. On day 35 of micromass pellet cultures 3 – 5 
pellets were pooled from each donor. COL2A1 mRNA expression demonstrates 
variations between the 9 tested donors (a). These donors were separated into 5 good 
donors (3, 4, 5, 8, 9) and 4 bad donors (1, 2, 6, 7) with a significant difference (b). *p 
< 0.05. 
		
 
Fig. 3. Alcian blue and collagen type II staining (a). The immunohistological 
evaluation demonstrates weak or absent Alcian blue and collagen type II staining for 
bad donors (D1, D2, D6, D7) but intense staining for good donors (D3, D4, D5, D8, 
D9). Bar = 100µm. Pellet size of 3D chondrogenic micromass pellets measured in 
differentiation media over time (day 7, 14, 21, 28 and 35) (b). The pellet diameter 
		
area of each good and bad donor corroborates the immunohistological stainings for 
Alcian blue and collagen type II. Apart from Donor 2, which is in the range of the 
good donors but still negative for Alcian blue and collagen type II staining.	
 
Fig. 4. Activation of Col2A luciferase reporter under 3D culture conditions. Micromass 
pellets were co-transfected with Metridia luciferase based reporter gene 
pCMVE_ACDCII-MetLuc together with Renilla control plasmid. Pellets were 
incubated in chondrogenic differentiation media with TGF-ß3 and BMP-6. Col2A 
Metridia luciferase activity was measured in the supernatant on day 1, day 2 and day 
3. For measurement of Renilla luciferase activity pellets were lysed on day3. 
Activation of Metridia and Renilla luciferase reporter and normalization of Metridia 
luciferase to Renilla luciferase on day3 for each single donor (a-c). There was a clear 
difference in the activation of Col2A reporter (a) while Renilla activation was similar in 
all tested donors (b). These differences were still present after normalization of 
Metridia to Renilla activation (c).  Donors were divided in good and bad donors as 
confirmed with qRT-PCR and regarding their specific reporter activation. Analysis of 
		
Col2A reporter activation over 3 days showed an increase for both groups, but 
significant higher Col2A activation for good donors (d). Even after normalization of 
Col2A activation to Renilla activation the induction of Col2A reporter was much 
stronger in good donors compared to bad donors (e). Data are shown as mean ± SD. 
Asterisks indicate significant difference. Units of Col2A luciferase reporter activation 
are shown in Relative Light Units (RLU). *p < 0.05; ****p < 0.0001	
 
Fig. 5. Activation of Col2A luciferase reporter under 2D culture conditions.  ASCs 
were co-transfected with Metridia luciferase based reporter gene pCMVE_ACDCII-
MetLuc together with Renilla control plasmid and incubated for 3 days with 
chondrogenic differentiation media with TGF-ß3 and BMP-6. On day 1, day 2 and 
day 3 Col2A Metridia luciferase activity was measured in the supernatant. On day 3 
cells were lysed for measurement of Renilla luciferase activity. Activation of Metridia 
and Renilla luciferase reporter and normalization of Metridia luciferase to Renilla 
luciferase on day3 for each single donor (a-c). There was a clear difference in the 
activation of Col2A reporter between the donors (a) while Renilla activation was 
similar in all tested donors (b). These differences were still present after 
		
normalization of Metridia to Renilla activation (c). Donors were divided in good and 
bad donors as confirmed with qRT-PCR and regarding their specific reporter 
activation. Analysis of Col2A reporter activation over 3 days showed an increase for 
both groups, but significant higher Col2A activation for good donors (d). Even after 
normalization of Col2A activation to Renilla activation the induction of Col2A reporter 
was higher in good donors compared to bad donors (e). Data are shown as mean ± 
SD. Asterisks indicate significant difference. Units of Col2A luciferase reporter 
activation are shown in Relative Light Units (RLU). *p < 0.05; **p < 0.01  
	
Fig. 6. Relation of Col2A luciferase reporter activation to Col2A1 mRNA expression, 
collagen type II immunostaining and pellet diameter area. Data of single donors are 
displayed with luciferase reporter activation on the x-axis and mRNA expression (a), 
immunostaining intensity (b) and the pellet diameter area (c) on the respective y-axis. 
A horizontal and vertical line indicate the cut-off point  discriminating the good donors 
		
3, 4, 5, 8, 9 and bad donors 1, 2, 6, 7  characterized by Col2A1 mRNA expression 
level (a) and colIagen II immunostaining intensity (b) based on Col2A luciferase 
reporter activation. In contrast plotting pellet diameter area against the luciferase 
reporter activation (c) showed no clear cut-off line to discriminate good and bad 
donors.  
 
 
 
 
Marker Mean ± SD 
CD73 99.68% ± 0.35 
CD90 98.70% ± 1.46 
CD105 97.95% ± 1.62 
HLA-ABC 93.74% ± 6.17 
HLA-DR 01.71% ± 0.76 
CD14 01.64% ± 0.87 
CD34 03.90% ± 7.69 
CD45 01.23% ± 0.52 
 
Table 1 
Supplemental Table 1. Immunophenotype of ASC at passage 1. ASC displayed 
strong expression of mesenchymal stem cell marker CD73, CD90 and CD105 and 
almost no expression of CD14 (lymphatic), CD34 (endothelial) and CD45 
(hematopoietic) which verified the ASC character. The histocompatibility antigen 
molecule HLA-ABC was expressed at a very high level whereas only a small portion 
of ASC expressed the histocompatibility antigen class II HLA-DR. 
	
		
	
Supplemental Fig. 1. GFP transfection of micromass pellet cultures. Un-transfected 
(left) and transfected (right) micromass pellets. Although the conventional 
autofluorescence is visible in un-transfected pellets, a clear positive signal for GFP is 
visible in transfected pellets (a) as well as 2D monolayer cell culture (b). Bar = 200µm 
(a), 100µm (b).  
 
		
 
Supplemental Fig. 2. SOX9 mRNA expression. On day 3 of micromass pellet 
cultures SOX9 demonstrates a very low expression in all single donors (a). There 
was no difference obvious when dividing the defined good donors (3, 4, 5, 8, 9) and 
bad donors (1, 2, 6, 7) (b). 
 
 
 
 
 
 
 
 
 
 
 
